Covered recipient · General Payments record
ALAN PIERRE ZAUSNER SKARBNIK
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$135,844.88
107 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,467.50 | 35 |
| Consulting Fee | $29,511.25 | 16 |
| Travel and Lodging | $9,298.74 | 28 |
| Food and Beverage | $2,567.39 | 27 |
| Honoraria | $2,000.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $59,769.80 | 50 |
| BeiGene USA, Inc. | $17,649.60 | 10 |
| Janssen Biotech, Inc. | $12,923.35 | 6 |
| JAZZ PHARMACEUTICALS INC. | $9,946.06 | 7 |
| Pharmacyclics LLC, An AbbVie Company | $7,596.03 | 9 |
| AbbVie Inc. | $7,120.24 | 6 |
| ADC Therapeutics America, Inc. | $5,868.76 | 5 |
| Kite Pharma, Inc. | $5,105.00 | 3 |
| Genentech USA, Inc. | $2,740.00 | 2 |
| AstraZeneca UK Limited | $1,665.00 | 1 |
| Novartis Pharmaceuticals Corporation | $1,485.00 | 1 |
| Alexion Pharmaceuticals, Inc. | $1,250.00 | 1 |
| MorphoSys, US Inc. | $1,217.50 | 1 |
| Lilly USA, LLC | $700.00 | 1 |
| TG THERAPEUTICS, INC. | $555.94 | 2 |
| Secura Bio, Inc. | $127.60 | 1 |
| GENZYME CORPORATION | $125.00 | 1 |
Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALAN PIERRE ZAUSNER SKARBNIK
NPI 1366754954 · CMS profile ID 914590
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
107 matching records · $135,844.88 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 107.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $125.00 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843640261 | CMS |
| JAZZ PHARMACEUTICALS INC. | $2,940.00 | 08/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845607843 | CMS |
| BeiGene USA, Inc. | $1,950.00 | 08/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696983 | CMS |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845607841 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,450.00 | 07/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829467315 | CMS |
| JAZZ PHARMACEUTICALS INC. | $759.50 | 07/29/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845607839 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,450.00 | 07/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829367005 | CMS |
| AstraZeneca Pharmaceuticals LP | $700.08 | 07/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829549071 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.91 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829718865 | CMS |
| BeiGene USA, Inc. | $1,950.00 | 07/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696985 | CMS |
| AstraZeneca Pharmaceuticals LP | $305.92 | 07/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829498799 | CMS |
| AstraZeneca Pharmaceuticals LP | $70.38 | 07/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829721359 | CMS |
| AstraZeneca Pharmaceuticals LP | $160.46 | 07/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829757303 | CMS |
| AstraZeneca Pharmaceuticals LP | $118.97 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829998935 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,100.00 | 07/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830104095 | CMS |
| JAZZ PHARMACEUTICALS INC. | $2,940.00 | 06/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845607561 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 06/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829586347 | CMS |
| JAZZ PHARMACEUTICALS INC. | $120.78 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845607559 | CMS |
| AbbVie Inc. | $1,650.00 | 06/11/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796302291 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $16.92 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016477 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $20.00 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016479 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $149.84 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016481 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $150.18 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016483 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $347.97 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016485 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $529.07 | 06/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016487 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $4,100.00 | 06/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016489 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 05/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788162863 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,885.00 | 05/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830093477 | CMS |
| Janssen Biotech, Inc. | $500.00 | 05/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788162865 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $82.05 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016475 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,800.00 | 05/18/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829283107 | CMS |
| AbbVie Inc. | $825.00 | 05/17/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796302289 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 05/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829535189 | CMS |
| BeiGene USA, Inc. | $1,950.00 | 04/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696987 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $2,200.00 | 04/29/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781016473 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,450.00 | 04/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829808011 | CMS |
| AstraZeneca Pharmaceuticals LP | $172.28 | 04/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829333591 | CMS |
| AstraZeneca Pharmaceuticals LP | $236.29 | 04/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829388317 | CMS |
| AstraZeneca Pharmaceuticals LP | $69.21 | 04/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829649807 | CMS |
| AstraZeneca Pharmaceuticals LP | $119.84 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830084789 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,450.00 | 04/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829869611 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829766623 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.05 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829851323 | CMS |
| AstraZeneca Pharmaceuticals LP | $132.30 | 04/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830035159 | CMS |
| AstraZeneca Pharmaceuticals LP | $174.22 | 04/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830144425 | CMS |
| AstraZeneca Pharmaceuticals LP | $64.02 | 04/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830145491 | CMS |
| Secura Bio, Inc. | $127.60 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851660973 | CMS |
| Kite Pharma, Inc. | $1,800.00 | 04/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844424145 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,250.00 | 03/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783119231 | CMS |
| MorphoSys, US Inc. | $1,217.50 | 03/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854734881 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,407.49 | 2 |
| PY2025 | Principal investigator | $1,497,977.99 | 72 |
| PY2024 | Recipient | $1,045.54 | 2 |
| PY2024 | Principal investigator | $2,005,059.27 | 63 |
| PY2023 | Recipient | $185,946.08 | 4 |
| PY2023 | Principal investigator | $1,224,916.67 | 31 |
| PY2022 | Recipient | $54,759.00 | 1 |
| PY2022 | Principal investigator | $1,142,264.31 | 30 |
| PY2021 | Recipient | $5,321.43 | 5 |
| PY2021 | Principal investigator | $1,378,819.98 | 24 |
| PY2020 | Recipient | $2,100.00 | 2 |
| PY2020 | Principal investigator | $1,375,547.50 | 19 |
| PY2019 | Principal investigator | $51,073.12 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
74 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 12/31/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies | No dispute reported | 06/30/2026 | 1202532648 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,630.00 | 12/16/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069979 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,000.00 | 12/16/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069984 |
| Recipient | F. Hoffmann-La Roche AG | $977.45 | 12/12/2025 | Covered Recipient Physician | glofitamab atezo or glofitamab polatuzumab in R R NHL | No dispute reported | 06/30/2026 | 1211534256 |
| Recipient | F. Hoffmann-La Roche AG | $430.04 | 12/08/2025 | Covered Recipient Physician | glofitamab atezo or glofitamab polatuzumab in R R NHL | No dispute reported | 06/30/2026 | 1211534252 |
| Principal investigator 1 | ABBVIE INC. | $985.40 | 12/04/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418537 |
| Principal investigator 1 | AstraZeneca UK Limited | $48,026.80 | 12/04/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma | No dispute reported | 06/30/2026 | 1185538745 |
| Principal investigator 1 | ABBVIE INC. | $31,319.60 | 11/06/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202523407 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $804.96 | 11/06/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223268824 |
| Principal investigator 1 | ABBVIE INC. | $1,830.40 | 11/05/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202522483 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $13,383.00 | 11/05/2025 | Non-covered Recipient Entity Novant Health Clinical Research Llc | Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release | No dispute reported | 06/30/2026 | 1235995129 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,345.00 | 11/05/2025 | Non-covered Recipient Entity Novant Health Clinical Research Llc | Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release | No dispute reported | 06/30/2026 | 1235995131 |
| Principal investigator 1 | ABBVIE INC. | $985.40 | 11/04/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418534 |
| Principal investigator 1 | ABBVIE INC. | $18,989.10 | 10/23/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202518419 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 10/21/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202517677 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,771.00 | 10/21/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069972 |
| Principal investigator 1 | Kite Pharma, Inc. | $33,952.62 | 10/21/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069976 |
| Principal investigator 1 | ABBVIE INC. | $52,760.50 | 10/16/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202517399 |
| Principal investigator 1 | ABBVIE INC. | $1,550.90 | 10/09/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418530 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,950.00 | 10/07/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252498733 |
| Principal investigator 1 | Genentech, Inc. | $1,305.00 | 10/06/2025 | Non-covered Recipient Entity PRESBYTERIAN HOSPITAL CANCER CENTER | glofitamab atezo or glofitamab polatuzumab in R R NHL | No dispute reported | 06/30/2026 | 1211638837 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,100.00 | 09/16/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069963 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,630.00 | 09/16/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069968 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 09/11/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202418526 |
| Principal investigator 1 | Celgene Corporation | $9,866.00 | 09/10/2025 | Non-covered Recipient Entity Novant Health Clinical Research Llc | Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release | No dispute reported | 06/30/2026 | 1222306553 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 09/09/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202510342 |
| Principal investigator 1 | ABBVIE INC. | $1,830.40 | 09/04/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202509796 |
| Principal investigator 1 | ABBVIE INC. | $150.80 | 09/02/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202507101 |
| Principal investigator 1 | ABBVIE INC. | $3,705.00 | 08/27/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202505963 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,630.00 | 08/19/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069959 |
| Principal investigator 1 | ABBVIE INC. | $27,275.22 | 08/05/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202501098 |
| Principal investigator 1 | ABBVIE INC. | $41,071.03 | 08/01/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202500912 |
| Principal investigator 1 | ABBVIE INC. | $3,350.00 | 07/31/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202418524 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 07/25/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202499888 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,771.00 | 07/22/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069955 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 07/08/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202497304 |
| Principal investigator 1 | ABBVIE INC. | $1,550.90 | 07/02/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418520 |
| Principal investigator 1 | ABBVIE INC. | $1,830.40 | 07/02/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202495681 |
| Principal investigator 1 | ABBVIE INC. | $1,550.90 | 06/03/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418514 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,463.30 | 05/29/2025 | Non-covered Recipient Entity Novant Health Hematology - Charlotte | A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190331457 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,630.00 | 05/20/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069951 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,430.80 | 05/14/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185538739 |
| Principal investigator 1 | BeiGene, Ltd. | $2,903.00 | 05/02/2025 | Non-covered Recipient Entity Novant Health Hematology - Charlotte | A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190322428 |
| Principal investigator 1 | ABBVIE INC. | $1,700.00 | 04/22/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202478233 |
| Principal investigator 1 | ABBVIE INC. | $1,127.10 | 04/22/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202478238 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,401.00 | 04/22/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069946 |
| Principal investigator 1 | ABBVIE INC. | $2,609.75 | 04/03/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202468872 |
| Principal investigator 1 | ABBVIE INC. | $4,288.70 | 04/02/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202468506 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 03/27/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202418506 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,955.00 | 03/18/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069942 |
| Principal investigator 1 | ABBVIE INC. | $1,579.50 | 03/07/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418502 |
| Principal investigator 1 | ABBVIE INC. | $12,426.70 | 03/07/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202462150 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 02/27/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418497 |
| Principal investigator 1 | ABBVIE INC. | $1,925.00 | 02/21/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202453563 |
| Principal investigator 1 | Kite Pharma, Inc. | $19,710.00 | 02/19/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069938 |
| Principal investigator 1 | BeiGene, Ltd. | $3,650.00 | 02/03/2025 | Non-covered Recipient Entity Novant Health Clinical Research | A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190320510 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,950.00 | 02/03/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496813 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $650.00 | 02/03/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496815 |
| Principal investigator 1 | Genentech, Inc. | $1,038.00 | 01/28/2025 | Non-covered Recipient Entity PRESBYTERIAN HOSPITAL CANCER CENTER | glofitamab atezo or glofitamab polatuzumab in R R NHL | No dispute reported | 06/30/2026 | 1211638833 |
| Principal investigator 1 | AstraZeneca UK Limited | $627,430.98 | 01/27/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma | No dispute reported | 06/30/2026 | 1185538743 |
| Principal investigator 1 | Acerta Pharma LLC | $50,533.60 | 01/23/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation | No dispute reported | 06/30/2026 | 1185538741 |
| Principal investigator 1 | Eli Lilly and Company | $103,681.52 | 01/22/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187873373 |
| Principal investigator 1 | Kite Pharma, Inc. | $14,150.00 | 01/22/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1212069934 |
| Principal investigator 1 | Genentech, Inc. | $870.00 | 01/21/2025 | Non-covered Recipient Entity PRESBYTERIAN HOSPITAL CANCER CENTER | glofitamab atezo or glofitamab polatuzumab in R R NHL | No dispute reported | 06/30/2026 | 1211638829 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,726.00 | 01/21/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496817 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $650.00 | 01/21/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496819 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,811.00 | 01/21/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496821 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $390.00 | 01/21/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496823 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,600.00 | 01/21/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | 101623 | No dispute reported | 06/30/2026 | 1252496825 |
| Principal investigator 1 | Celgene Corporation | $184,688.65 | 01/17/2025 | Covered Recipient Teaching Hospital Presbyterian Hospital Huntersville | A Phase 2, open-label, single arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 (lisocabtagene maraleucel) in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) | No dispute reported | 06/30/2026 | 1222306217 |
| Principal investigator 1 | ABBVIE INC. | $16,064.56 | 01/13/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202418493 |
| Principal investigator 1 | ABBVIE INC. | $86,378.50 | 01/10/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202437990 |
| Principal investigator 1 | Eli Lilly and Company | $1,730.20 | 01/09/2025 | Covered Recipient Teaching Hospital PRESBYTERIAN HOSPITAL HUNTERSVILLE | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187874897 |
| Principal investigator 1 | ABBVIE INC. | $1,333.80 | 01/02/2025 | Non-covered Recipient Entity NOVANT HEALTH CLINICAL RESEARCH LLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202434840 |